Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.
about
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsInsulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination StudiesMolecular characteristics and potential therapeutic targets in Merkel cell carcinoma.Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.Can insulin-like growth factor 1 (IGF-1), IGF-1 receptor connective tissue growth factor and Ki-67 labelling index have a prognostic role in pulmonary carcinoids?
P2860
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase I study of the anti-IGF1 ...... ntiated neuroendocrine tumors.
@ast
Phase I study of the anti-IGF1 ...... ntiated neuroendocrine tumors.
@en
type
label
Phase I study of the anti-IGF1 ...... ntiated neuroendocrine tumors.
@ast
Phase I study of the anti-IGF1 ...... ntiated neuroendocrine tumors.
@en
prefLabel
Phase I study of the anti-IGF1 ...... ntiated neuroendocrine tumors.
@ast
Phase I study of the anti-IGF1 ...... ntiated neuroendocrine tumors.
@en
P2093
P2860
P356
P1476
Phase I study of the anti-IGF1 ...... ntiated neuroendocrine tumors.
@en
P2093
Alexandria Phan
Arvind Dasari
Asif Rashid
Caimiao Wei
Daniel Halperin
Emily Tarco
Helen Chen
Huiqin Chen
Kenneth Hess
P2860
P304
P356
10.1530/ERC-15-0002
P577
2015-04-21T00:00:00Z